CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to BMY

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Renal Cell Carcinoma, Clear Cell

View Full Landscape
Drug Information

Target Indication

Renal Cell Carcinoma, Clear Cell

Clinical Trial

NCT06708949

Last updated: 10/24/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMA7/20/2015

Nivolumab BMS

Nivolumab BMS is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.